Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q3 revenue rises 8.3% to $533.3 million; diluted EPS $3.01 vs. $2.22

Positive Impact 3 of 5 earnings Written later

Medpace reported third-quarter 2024 revenue of $533.3 million, up 8.3% from a year earlier, and GAAP net income of $96.4 million, or $3.01 per diluted share, versus $2.22 in the prior-year quarter. Net new business awards fell 12.7% to $533.7 million, but the net book-to-bill ratio was 1.00x and backlog rose 8.8% to $2,927.4 million. The company forecast full-year 2024 revenue of $2.090 billion to $2.130 billion and GAAP diluted EPS of $11.71 to $12.09.

Key points

  • Q3 2024 revenue was $533.3 million, up 8.3% from $492.5 million; EBITDA rose 31.7% to $118.8 million.
  • Q3 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus $2.22 a year earlier.
  • Net new business awards were $533.7 million, down 12.7% from $611.5 million; backlog was $2,927.4 million as of September 30, 2024.
  • 2024 guidance: revenue of $2.090 billion to $2.130 billion and GAAP diluted EPS of $11.71 to $12.09.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECOct 21, 2024, 4:15 PM ET
Accession number0001668397-24-000165

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.